These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2242 related articles for article (PubMed ID: 29097493)

  • 1. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.
    Gopalakrishnan V; Spencer CN; Nezi L; Reuben A; Andrews MC; Karpinets TV; Prieto PA; Vicente D; Hoffman K; Wei SC; Cogdill AP; Zhao L; Hudgens CW; Hutchinson DS; Manzo T; Petaccia de Macedo M; Cotechini T; Kumar T; Chen WS; Reddy SM; Szczepaniak Sloane R; Galloway-Pena J; Jiang H; Chen PL; Shpall EJ; Rezvani K; Alousi AM; Chemaly RF; Shelburne S; Vence LM; Okhuysen PC; Jensen VB; Swennes AG; McAllister F; Marcelo Riquelme Sanchez E; Zhang Y; Le Chatelier E; Zitvogel L; Pons N; Austin-Breneman JL; Haydu LE; Burton EM; Gardner JM; Sirmans E; Hu J; Lazar AJ; Tsujikawa T; Diab A; Tawbi H; Glitza IC; Hwu WJ; Patel SP; Woodman SE; Amaria RN; Davies MA; Gershenwald JE; Hwu P; Lee JE; Zhang J; Coussens LM; Cooper ZA; Futreal PA; Daniel CR; Ajami NJ; Petrosino JF; Tetzlaff MT; Sharma P; Allison JP; Jenq RR; Wargo JA
    Science; 2018 Jan; 359(6371):97-103. PubMed ID: 29097493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.
    Matson V; Fessler J; Bao R; Chongsuwat T; Zha Y; Alegre ML; Luke JJ; Gajewski TF
    Science; 2018 Jan; 359(6371):104-108. PubMed ID: 29302014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.
    Baruch EN; Youngster I; Ben-Betzalel G; Ortenberg R; Lahat A; Katz L; Adler K; Dick-Necula D; Raskin S; Bloch N; Rotin D; Anafi L; Avivi C; Melnichenko J; Steinberg-Silman Y; Mamtani R; Harati H; Asher N; Shapira-Frommer R; Brosh-Nissimov T; Eshet Y; Ben-Simon S; Ziv O; Khan MAW; Amit M; Ajami NJ; Barshack I; Schachter J; Wargo JA; Koren O; Markel G; Boursi B
    Science; 2021 Feb; 371(6529):602-609. PubMed ID: 33303685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC.
    Jin Y; Dong H; Xia L; Yang Y; Zhu Y; Shen Y; Zheng H; Yao C; Wang Y; Lu S
    J Thorac Oncol; 2019 Aug; 14(8):1378-1389. PubMed ID: 31026576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
    Routy B; Le Chatelier E; Derosa L; Duong CPM; Alou MT; Daillère R; Fluckiger A; Messaoudene M; Rauber C; Roberti MP; Fidelle M; Flament C; Poirier-Colame V; Opolon P; Klein C; Iribarren K; Mondragón L; Jacquelot N; Qu B; Ferrere G; Clémenson C; Mezquita L; Masip JR; Naltet C; Brosseau S; Kaderbhai C; Richard C; Rizvi H; Levenez F; Galleron N; Quinquis B; Pons N; Ryffel B; Minard-Colin V; Gonin P; Soria JC; Deutsch E; Loriot Y; Ghiringhelli F; Zalcman G; Goldwasser F; Escudier B; Hellmann MD; Eggermont A; Raoult D; Albiges L; Kroemer G; Zitvogel L
    Science; 2018 Jan; 359(6371):91-97. PubMed ID: 29097494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients.
    Davar D; Dzutsev AK; McCulloch JA; Rodrigues RR; Chauvin JM; Morrison RM; Deblasio RN; Menna C; Ding Q; Pagliano O; Zidi B; Zhang S; Badger JH; Vetizou M; Cole AM; Fernandes MR; Prescott S; Costa RGF; Balaji AK; Morgun A; Vujkovic-Cvijin I; Wang H; Borhani AA; Schwartz MB; Dubner HM; Ernst SJ; Rose A; Najjar YG; Belkaid Y; Kirkwood JM; Trinchieri G; Zarour HM
    Science; 2021 Feb; 371(6529):595-602. PubMed ID: 33542131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiome and immunotherapy response.
    Burki TK
    Lancet Oncol; 2017 Dec; 18(12):e717. PubMed ID: 29129446
    [No Abstract]   [Full Text] [Related]  

  • 8. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.
    Sivan A; Corrales L; Hubert N; Williams JB; Aquino-Michaels K; Earley ZM; Benyamin FW; Lei YM; Jabri B; Alegre ML; Chang EB; Gajewski TF
    Science; 2015 Nov; 350(6264):1084-9. PubMed ID: 26541606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance.
    Park JS; Gazzaniga FS; Wu M; Luthens AK; Gillis J; Zheng W; LaFleur MW; Johnson SB; Morad G; Park EM; Zhou Y; Watowich SS; Wargo JA; Freeman GJ; Kasper DL; Sharpe AH
    Nature; 2023 May; 617(7960):377-385. PubMed ID: 37138075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers.
    Mao J; Wang D; Long J; Yang X; Lin J; Song Y; Xie F; Xun Z; Wang Y; Wang Y; Li Y; Sun H; Xue J; Song Y; Zuo B; Zhang J; Bian J; Zhang T; Yang X; Zhang L; Sang X; Zhao H
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34873013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjunctive Probiotic
    Gao G; Ma T; Zhang T; Jin H; Li Y; Kwok LY; Zhang H; Sun Z
    Front Immunol; 2021; 12():772532. PubMed ID: 34970262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The intimate relationship between gut microbiota and cancer immunotherapy.
    Elkrief A; Derosa L; Zitvogel L; Kroemer G; Routy B
    Gut Microbes; 2019; 10(3):424-428. PubMed ID: 30339501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma.
    Zheng Y; Wang T; Tu X; Huang Y; Zhang H; Tan D; Jiang W; Cai S; Zhao P; Song R; Li P; Qin N; Fang W
    J Immunother Cancer; 2019 Jul; 7(1):193. PubMed ID: 31337439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microbiome modulates immunotherapy response in cutaneous squamous cell carcinoma.
    Voigt AY; Walter A; Young TH; Graham JP; Batista Bittencourt BM; de Mingo Pulido A; Prieto K; Tsai KY; Sundberg JP; Oh J
    Exp Dermatol; 2023 Oct; 32(10):1624-1632. PubMed ID: 37350109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small-cell lung cancer patients.
    Zhang C; Wang J; Sun Z; Cao Y; Mu Z; Ji X
    Cancer Sci; 2021 Aug; 112(8):3005-3017. PubMed ID: 34028936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.
    Borgers JSW; Burgers FH; Terveer EM; van Leerdam ME; Korse CM; Kessels R; Flohil CC; Blank CU; Schumacher TN; van Dijk M; Henderickx JGE; Keller JJ; Verspaget HW; Kuijper EJ; Haanen JBAG
    BMC Cancer; 2022 Dec; 22(1):1366. PubMed ID: 36585700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients.
    Peters BA; Wilson M; Moran U; Pavlick A; Izsak A; Wechter T; Weber JS; Osman I; Ahn J
    Genome Med; 2019 Oct; 11(1):61. PubMed ID: 31597568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of the gut microbiota in predicting response to cancer immunotherapy in metastatic melanoma.
    Limeta A; Ji B; Levin M; Gatto F; Nielsen J
    JCI Insight; 2020 Dec; 5(23):. PubMed ID: 33268597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.
    Spencer CN; McQuade JL; Gopalakrishnan V; McCulloch JA; Vetizou M; Cogdill AP; Khan MAW; Zhang X; White MG; Peterson CB; Wong MC; Morad G; Rodgers T; Badger JH; Helmink BA; Andrews MC; Rodrigues RR; Morgun A; Kim YS; Roszik J; Hoffman KL; Zheng J; Zhou Y; Medik YB; Kahn LM; Johnson S; Hudgens CW; Wani K; Gaudreau PO; Harris AL; Jamal MA; Baruch EN; Perez-Guijarro E; Day CP; Merlino G; Pazdrak B; Lochmann BS; Szczepaniak-Sloane RA; Arora R; Anderson J; Zobniw CM; Posada E; Sirmans E; Simon J; Haydu LE; Burton EM; Wang L; Dang M; Clise-Dwyer K; Schneider S; Chapman T; Anang NAS; Duncan S; Toker J; Malke JC; Glitza IC; Amaria RN; Tawbi HA; Diab A; Wong MK; Patel SP; Woodman SE; Davies MA; Ross MI; Gershenwald JE; Lee JE; Hwu P; Jensen V; Samuels Y; Straussman R; Ajami NJ; Nelson KC; Nezi L; Petrosino JF; Futreal PA; Lazar AJ; Hu J; Jenq RR; Tetzlaff MT; Yan Y; Garrett WS; Huttenhower C; Sharma P; Watowich SS; Allison JP; Cohen L; Trinchieri G; Daniel CR; Wargo JA
    Science; 2021 Dec; 374(6575):1632-1640. PubMed ID: 34941392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The gut microbiota and immune checkpoint inhibitors.
    Humphries A; Daud A
    Hum Vaccin Immunother; 2018; 14(9):2178-2182. PubMed ID: 29494275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 113.